Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma

NCT05545969 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Insufficient funding

Conditions

Mucosal Melanoma

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

Melanoma Institute Australia

Collaborators

[object Object]